BCG vaccine provides protection against influenza virus but not SARS-CoV-2
A new study led by RI-MUHC researchers reveals that the 100-year-old tuberculosis vaccine known as..
Beyond basic research: Coming to grips with a rare disease experience
To honour Rare Disease Day on February 28, an RI-MUHC research trainee shares the perspective he gained as a patient
RI-MUHC team uncovers new mechanism of inflammation in muscular dystrophy
A new study reveals how signals sent from damaged muscles to the bone marrow can induce long-lasting...
Fall 2021 CIHR competition results
RI-MUHC teams received $9.5 million in project funding
Three renewed Canada Research Chairs for RI-MUHC researchers
Ahmad Haidar, Dennis Jensen and Ian Watson are part of the McGill University cohort of 17 new and renewed Canada Research Chairs
Promising COVID-19 therapeutic drug to start phase 3 clinical trial in the United States
Recruitment of first U.S.-based patients in dapsone trial has started
Research on dysanapsis recognized by McGill Medstar Award for Trainees
Congratulations to RI-MUHC trainee Motahareh Vameghestahbanati!
Can inhaled corticosteroids alleviate early symptoms of COVID-19?
Results from the CONTAIN study conducted at the RI-MUHC reveal that ciclesonide is no better than placebo
Regular screening for tuberculosis in Inuit communities is cost-effective
A new study from RI-MUHC researchers published in CMAJ recommends regular screening to help reduce outbreaks
Ben Geboe awarded the 2021-2022 Dr. Margaret Becklake Fellowship for his research with urban Indigenous populations
The RI-MUHC postdoc is working on a culturally safe framework for TB...